Celecoxib Does Not Attenuate the Antiplatelet Effects of Aspirin and Clopidogrel in Healthy Volunteers

다국어 초록 (Multilingual Abstract)

Background and Objectives: The prevalence of arthritis, which is often treated with celecoxib, is high in patients with coronary artery disease. Furthermore, celecoxib has been reported to reduce restenosis after coronary stenting by inhibiting expression of the proto-oncogene Akt. A concern is that celecoxib increases thrombogenicity by inhibiting the synthesis of prostacyclin in endothelial cells. However, it is not known whether the administration of celecoxib will attenuate the antiplatelet effects of aspirin and clopidogrel, which are used after stenting. We addressed this gap in our knowledge. Subjects and Methods: We recruited healthy volunteers (n=40) and randomized them into five subgroups (n=8 for each group: aspirin,celecoxib, aspirin+celecoxib, aspirin+clopidogrel, and aspirin+clopidogrel+celecoxib). Each subject received their medications for 6 days and blood samples were taken on day 0 and day 7. Celecoxib (200 mg twice a day), and/or aspirin (100 mg daily),and/or clopidogrel (75 mg daily) were administered. We compared platelet function among subgroups using light transmittance aggregometry and arachidonic acid metabolite assays. Results: Celecoxib treatment alone did not significantly affect platelet aggregation. The reduction in adenosine diphosphase (ADP)-induced platelet aggregation by aspirin+clopidogrel was not affected by addition of celecoxib (31.3±6.9% vs. 32.4±12.2%, p=0.83). Inhibition of collagen-induced platelet aggregation by aspirin+clopidogrel was not affected by addition of celecoxib (47.6±13.4% vs. 51.6±3.7%, p=0.69). Drug-induced changes in prostacyclin and thromboxane levels did not differ among treatment groups. Conclusion: Celecoxib treatment does not interfere with the antiplatelet effects of aspirin or clopidogrel, suggesting that celecoxib can be safely administered in combination with dual antiplatelet therapy in patients with coronary stenting without increased thrombogenicity.

참고문헌 (Reference)

1 김성수, "Very Late Thrombosis of a Drug-Eluting Stent After Discontinuation of Dual Antiplatelet Therapy in a Patient Treated With Both Drug-Eluting and Bare-Metal Stents" 대한심장학회 39 (39): 205-208, 2009

2 Steinbach G, "The effect of celecoxib,a cyclooxygenase-2 inhibitor,in familial adenomatous polyposis" 342 : 1946-1952, 2000

3 FitzGerald GA, "The coxibs,selective inhibitors of cyclooxygenase-2" 345 : 433-442, 2001

4 Hawk E, "The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials:stepping stones to progress" 16 : 185-187, 2007

5 McAdam BF, "Systemic biosynthesis of prostacyclin by cyclooxygenase(COX)-2:the human pharmacology of a selective inhibitor of COX-2" 96 : 272-277, 1999

6 Kobayashi T, "Roles of thromboxane A(2)and prostacyclin in the development of atherosclerosis in apoEdeficient mice" 114 : 784-794, 2004

7 Johnsen SP, "Risk of hospitalization for myocardial infarction among users of rofecoxib,celecoxib,and other NSAIDs:a population-based case-control study" 165 : 978-984, 2005

8 White WB, "Risk of cardiovascular events in patients receiving celecoxib:a meta-analysis of randomized clinical trials" 99 : 91-98, 2007

9 Nieswandt B, "Platelet-collagen interaction:is GPVI the central receptor?" 102 : 449-461, 2003

10 Van Ryn J, "Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers" 44 : 777-784, 2004

11 Arrebola MM, "In vitro effects of clopidogrel on the plateletsubendothelium interaction,platelet thromboxane and endothelial prostacyclin production,and nitric oxide synthesis" 43 : 74-82, 2004

12 Silverstein FE, "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis:the CLASS study:a randomized controlled trial.Celecoxib Long-term Arthritis Safety Study" 284 : 1247-1255, 2000

13 Leese PT, "Effects of celecoxib,a novel cyclooxygenase-2 inhibitor,on platelet function in healthy adults:a randomized,controlled trial" 40 : 124-132, 2000

14 Koo BK, "Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent(COREA-TAXUS trial):an open-label randomised controlled study" 370 : 567-574, 2007

15 Belton O, "Cyclooxygenase-1 and-2-dependent prostacyclin formation in patients with atherosclerosis" 102 : 840-845, 2000

16 Antman EM, "Cyclooxygenase inhibition and cardiovascular risk" 112 : 759-770, 2005

17 Fitzgerald GA, "Coxibs and cardiovascular disease" 351 : 1709-1711, 2004

18 Park JC, "Clinical characteristics of coronary interventions in old aged patients" 28 : 256-261, 1998

19 Renda G, "Celecoxib,ibuprofen,and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease" 80 : 264-274, 2006

20 Wang K, "Celecoxib,a selective cyclooxygenase-2 inhibitor,decreases monocyte chemoattractant protein1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model" 45 : 61-67, 2005

21 Yang HM, "Celecoxib,a cyclooxygenase-2 inhibitor,reduces neointimal hyperplasia through inhibition of Akt signaling" 110 : 301-308, 2004

22 Wilner KD, "Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers" 42 : 1027-1030, 2002

23 Steffel J, "Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation" 111 : 1685-1689, 2005

24 Solomon SD, "Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials:the cross trial safety analysis" 117 : 2104-2113, 2008

25 Solomon SD, "Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention" 352 : 1071-1080, 2005

26 McGettigan P, "Cardiovascular risk and inhibition of cyclooxygenase:a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2" 296 : 1633-1644, 2006

27 Bresalier RS, "Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial" 352 : 1092-1102, 2005

28 ADAPT Research Group, "Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT)" 1 : e33-, 2006

29 채성철, "Antiplatelet Agents in High-Risk Patients with Coronary Artery Disease" 대한심장학회 34 (34): 23-27, 2004

30 Fiorina P, "Altered kidney graft highenergy phosphate metabolism in kidney-transplanted endstage renal disease type 1 diabetic patients:a cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation" 30 : 597-603, 2007